Loading
A phase 2 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by CG Oncology, Inc., now recruiting.
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC is a phase 2 interventional study registered as NCT06567743 by CG Oncology, Inc., with 325 participants planned, started 2024-09-16 and due to reach its primary completion in 2027-03-31. Interventions recorded: Cretostimogene Grenadenorepvec.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CG Oncology, Cretostimogene grenadenorepvec, Non-muscle-invasive bladder cancer, Oncolytic viruses and the tag pipeline.
Shares Cretostimogene grenadenorepvec, Non-muscle-invasive bladder cancer, Oncolytic viruses, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer, Bladder & urothelial cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/